KDIGO Opens 2026 Draft Guideline for Public Review: Learn more

Announcements

Investor News

BioPorto A/S

BioPorto A/S to host an investor webcast on the results for the first quarter of 2026

Tue, 12 May 2026 05:58 GMT

BioPorto A/S

BioPorto A/S afholder webcast for investorer om resultatet for første kvartal 2026

Tue, 12 May 2026 05:58 GMT

BioPorto A/S

Resolutions of the Annual General Meeting

Fri, 24 Apr 2026 14:22 GMT

BioPorto A/S

Forløb af den ordinære generalforsamling

Fri, 24 Apr 2026 14:22 GMT

BioPorto A/S

Grant of Warrants

Tue, 14 Apr 2026 18:01 GMT

BioPorto A/S

Tildeling af Warrants

Tue, 14 Apr 2026 18:01 GMT

BioPorto A/S

Major Shareholder Announcement

Mon, 13 Apr 2026 08:49 GMT

BioPorto A/S

Storaktionær Meddelelse

Mon, 13 Apr 2026 08:49 GMT

BioPorto A/S

BioPorto Successfully Completes Divestment of its Antibody Business to Janel Life Sciences, LLC

Wed, 08 Apr 2026 13:16 GMT

BioPorto A/S

BioPorto frasælger antistofforretning til Janel Life Sciences, LLC

Wed, 08 Apr 2026 13:16 GMT

BioPorto A/S

BioPorto Advances U.S. Adult Urine NGAL Program with FDA Pre-Submission Request After Positive EPACRA AKI Cut Off Analysis

Tue, 31 Mar 2026 15:43 GMT

BioPorto A/S

BioPorto indsender anmodning om FDA pre‑submission for amerikansk voksenprogram for urin‑NGAL efter positiv EPACRA‑analyse af AKI‑cut‑off

Tue, 31 Mar 2026 15:43 GMT

BioPorto A/S

KDIGO publishes 2026 Clinical Practice Guideline Draft for Acute Kidney Injury and Acute Kidney Disease

Tue, 31 Mar 2026 10:34 GMT

BioPorto A/S

KDIGO offentliggør udkast til klinisk praksis guideline 2026 for akut nyreskade og akut nyresygdom

Tue, 31 Mar 2026 10:34 GMT

BioPorto A/S

Notice convening the Annual General Meeting in BioPorto A/S

Thu, 26 Mar 2026 08:00 GMT

BioPorto A/S

Indkaldelse til ordinær generalforsamling i BioPorto A/S

Thu, 26 Mar 2026 08:00 GMT

BioPorto A/S

BioPorto announces the Annual Report for 2025

Thu, 26 Mar 2026 06:43 GMT

BioPorto A/S

BioPorto annoncerer Årsrapporten for 2025

Thu, 26 Mar 2026 06:43 GMT

BioPorto A/S

BioPorto Successfully Completes Preliminary Analysis of U.S. Adult NGAL Cutoff Study; Pre-Submission expected by End of Q1 2026

Wed, 18 Mar 2026 17:55 GMT

BioPorto A/S

BioPorto gennemfører succesfuld foreløbig analyse af det amerikanske voksne NGAL-cutoff-studie; Pre-submission forventes indsendt inden udgangen af første kvartal 2026

Wed, 18 Mar 2026 17:55 GMT

Follow this link to view all historical announcements.

Follow this link to view all historical announcements.